Diamide-1,2-dioxide acrylic-and MTR-Everolimus inhibitors containing 2-acylpyridine-1,2-dioxide-1,2-methyl-5 (2-(2,2,2-trifluoro-1,1-dimethyl) pyridine-4-1]-pyridine-4-acyl-amine were used to treat breast cancer； and drug syntheses were used. Use
The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mTOR) inhibitor or a pharmaceutically acceptable salt thereof； a pharmaceutical composition comprising such a combination； and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mTOR) kinase dependent diseases.USO DE UNA COMBINACIÓN FARMACÉUTICA QUE COMPRENDE EL COMPUESTO 1-({4-METIL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETILETIL)PIRIDIN-4-IL]-TIAZOL-2-IL}-AMIDA) DE 2-AMIDA DEL ÁCIDO (S) PIRROLIDIN-1,2-DICARBOXÍLICO Y EL INHIBIDOR DE MTOR EVEROLIMUS PARA TRATAR CÁNCER DE MAMA； Y USO DE LA COMPOSICIÓN FARMACÉUTICA
